Show simple item record

dc.contributor.authorFlavin, Richard
dc.contributor.authorPettersson, Andreas
dc.contributor.authorHendrickson, Whitney
dc.contributor.authorFiorentino, Michelangelo
dc.contributor.authorFinn, Stephen
dc.contributor.authorKunz, Lauren
dc.contributor.authorJudson, Gregory
dc.contributor.authorLis, Rosina
dc.contributor.authorBailey, Dyane
dc.contributor.authorFiore, Christopher
dc.contributor.authorNuttall, Elizabeth
dc.contributor.authorMartin, Neil
dc.contributor.authorStack, Edward
dc.contributor.authorPenney, Kathryn
dc.contributor.authorRider, Jennifer
dc.contributor.authorSinnott, Jennifer
dc.contributor.authorSweeney, Christopher
dc.contributor.authorSesso, Howard
dc.contributor.authorFall, Katja
dc.contributor.authorGiovannucci, Edward
dc.contributor.authorKantoff, Philip
dc.contributor.authorStampfer, Meir
dc.contributor.authorLoda, Massimo
dc.contributor.authorMucci, Lorelei
dc.date.accessioned2019-09-05T17:04:25Z
dc.date.issued2014
dc.identifier.citationFlavin, R., A. Pettersson, W. K. Hendrickson, M. Fiorentino, S. Finn, L. Kunz, G. L. Judson, et al. 2014. “SPINK1 Protein Expression and Prostate Cancer Progression.” Clinical Cancer Research 20 (18): 4904–11. https://doi.org/10.1158/1078-0432.ccr-13-1341.
dc.identifier.issn1078-0432
dc.identifier.issn1557-3265
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:41292538*
dc.description.abstractPurpose: SPINK1 overexpression has been described in prostate cancer and is linked with poor prognosis in many cancers. The objective of this study was to characterize the association between SPINK1 overexpression and prostate cancer-specific survival.Experimental Design: The study included 879 participants in the U. S. Physicians' Health Study and Health Professionals Follow-Up Study, diagnosed with prostate cancer (1983-2004) and treated by radical prostatectomy. Protein tumor expression of SPINK1 was evaluated by immunohistochemistry on tumor tissue microarrays. Results: Seventy-four of 879 (8%) prostate cancer tumors were SPINK1 positive. Immunohistochemical data were available for PTEN, p-Akt, pS6, stathmin, androgen receptor (AR), and ERG (as a measure of the TMPRSS2: ERG translocation). Compared with SPINK1-negative tumors, SPINK1-positive tumors showed higher PTEN and stathmin expression, and lower expression of AR (P < 0.01). SPINK1 overexpression was seen in 47 of 427 (11%) ERG-negative samples and in 19 of 427 (4%) ERG-positive cases (P = 0.0003). We found no significant associations between SPINK1 status and Gleason grade or tumor stage. There was no association between SPINK1 expression and biochemical recurrence (P = 0.56). Moreover, there was no association between SPINK1 expression and prostate cancer mortality (there were 75 lethal cases of prostate cancer during a mean of 13.5 years follow-up; HR = 0.71; 95% confidence interval, 0.29-1.76). Conclusions: Our results suggest that SPINK1 protein expression may not be a predictor of recurrence or lethal prostate cancer amongst men treated by radical prostatectomy. SPINK1 and ERG protein expression do not seem to be entirely mutually exclusive, as some previous studies have suggested.
dc.language.isoen_US
dc.publisherAmerican Association for Cancer Research
dash.licenseOAP
dc.titleSPINK 1 Protein Expression and Prostate Cancer Progression
dc.typeJournal Article
dc.description.versionAccepted Manuscript
dc.relation.journalClinical Cancer Research
dash.depositing.authorStampfer, Meir
dc.date.available2019-09-05T17:04:25Z
dash.workflow.comments1Science Serial ID 26236
dc.identifier.doi10.1158/1078-0432.CCR-13-1341
dash.source.volume20;18
dash.source.page4904
dash.contributor.affiliatedStampfer, Meir


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record